Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS)

Solitary Fibrous Tumor (SFT) is a rare mesenchymal tumor driven by the NAB2-STAT6 fusion oncogene. To investigate transcriptional changes induced by BET inhibition in SFT models, we performed bulk RNA sequencing of INT-SFT and IEC139 cell lines treated with the BET inhibitors Mivebresib (ABBV-075) or BMS-986158 (50 nM for 24 h). Total RNA was extracted and libraries were sequenced on the Illumina NovaSeq X platform. Gene-level expression was quantified using Salmon against the GRCh38 reference genome with GENCODE annotation. Differential expression and pathway enrichment analyses were performed to characterize transcriptional programs associated with BET inhibitor treatment.